Publicacións nas que colabora con Francisco Jorquera Plaza (16)

2024

  1. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Restablecimiento de la actividad en los servicios de Digestivo. Recomendaciones de la SEPD, AEEH, GETECCU y AEG

    Revista Española de Enfermedades Digestivas, Vol. 112, Núm. 5, pp. 397-411

  4. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 6, pp. 332-347

  5. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2018

  1. Acute hepatitis secondary to high-dose intravenous methylprednisolone

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 8, pp. 508-509

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Hepatitis aguda virus E autóctona: Un diagnóstico en aumento. Análisis clínico-epidemiológico de nuestra experiencia

    Revista Española de Enfermedades Digestivas, Vol. 109, Núm. 5, pp. 344-349

  4. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

2016

  1. Déficit de vitamina D en la enfermedad hepática crónica, análisis clínico epidemiológico y tras aporte vitamínico

    Gastroenterologia y Hepatologia, Vol. 39, Núm. 5, pp. 305-310

  2. Reactivación de tuberculosis pulmonar durante el tratamiento con triple terapia de la hepatitis C

    Gastroenterologia y Hepatologia, Vol. 39, Núm. 4, pp. 273-274

2015

  1. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153